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A sage who might also be considered one of the founding fathers
of gene therapy remarked recently that although it was clearly
advantageous to have been trained in molecular virology in the
beginning days of gene therapy, training focused on immunol-
ogy might be preferable for future gene therapy investigators.
He was alluding to the fact that although the ¢eld of gene ther-
apy has made signi¢cant progress in designing vectors for e⁄-
cient gene delivery to speci¢c tissues and cells, avoiding
unwanted immune responses to normal replacement gene
products remains a di⁄cult problem for the gene therapy ¢eld.
In this issue, an article by Ohyama and colleagues begins to
address this issue in an experimental animal model (Ohyama
et al, 2003). For skin gene therapy, both viral and nonviral vectors
continue to be incrementally improved in order to achieve more
e⁄cient and safe gene delivery and durable gene expression
(Ghazizadeh and Taichman, 2000; Vogel, 2000). In the future,
new vectors with custom-designed promoter-enhancers may
provide gene expression that is physiological and responsive to
environmental cues, or expression that can be regulated up
or down by external interventions such as a topical cream.
Additional advances driving skin gene therapy include the
ongoing characterization of the genes responsible for heritable
skin disease, many of which are recessive (Uitto and Pulkkinen,
2000), and the development of gene replacement strategies in
both animal models and clinical trials (Dellambra et al, 2000;
Khavari, 2000).
However, when recessive genetic skin disease is treated by
normal gene introduction, the development of unwanted
immune responses against the normal protein remains a signi-
¢cant concern because immunological epitopes that were not
present during thymic development will be expressed. If the
recipient is not tolerant to these new epitopes, or if tolerance
does not develop after gene replacement, an immune response
may ensue. Unwanted immune responses may also develop
against indicator genes (b-galactosidase or GFP (Green Fluores-
cent Protein)) or selectable marker genes that might be present
in the gene delivery vector (viral or nonviral). Some viral vectors,
such as the adenoviral vectors, contain many additional regula-
tory and structural genes that may also elicit strong immunologi-
cal responses in the host. These unwanted immune responses are
problematic because tissue cells expressing the new normal
protein could be targeted by a cellular immune response with
destruction of gene expressing cells, and eventually, loss of gene
expression. Furthermore, once an immune response has devel-
oped against the normal protein, it would be very di⁄cult to
re-introduce the desired normal gene at a later time.
Nature has already provided cautionary examples of how
autoimmune responses against important keratinocyte proteins,
such as adhesion molecules, can result in signi¢cant bullous dis-
eases. It should be noted that without actual experimental evi-
dence from clinical gene therapy studies, we don’t really know
how serious the problem of unwanted immune responses will
be when replacing either a missing or defective protein. In some
clinical situations, unwanted immune responses may be less likely
to develop following normal gene replacement. For example, re-
cessive skin diseases due to a speci¢c point mutation may result in
a functionally defective, but full-length protein that contains
most of the immunologically relevant epitopes so that gene re-
placement with a normal protein may not generate an unwanted
immune response. Unwanted immune responses are of particular
concern in skin because resident antigen presenting cells (APC),
such as Langerhans cells, are able to initiate vigorous immune re-
sponses, as has been frequently demonstrated when DNA vac-
cines are targeted to the skin (Larregina and Falo, 2000).
The hypothesis of Amagai and coworkers is that unwanted im-
mune responses against a neoantigen (desmoglein 3 or Dsg3) in a
DSG3 knock-out mouse can be prevented by blocking the co-
stimulatory interaction of CD40 on APC with CD40 Ligand
(CD40L) on CD4þ T-helper cells that is required for generating
an immune response. Induction and maintenance of clinical
tolerance is frequently di⁄cult to achieve, and remains an area
of active investigation (Miller, 2001). There are several typical
ways to induce tolerance in the clinical setting, including the use
of di¡erent combinations of immunosuppressive drugs and the
blockade of one or several of the costimulatory signals that
are necessary for T-cell activation. These authors chose the latter
option.
In this experimental model, wild type skin that expresses a
normal Dsg3 protein is grafted onto a Dsg3 knockout (^/^)
mouse that lacks Dsg3. This transplantation experiment can be
considered analogous to skin gene therapy that introduces the
normal Dsg3 gene into skin where normal Dsg3 expression is
lacking.The authors blocked the necessary costimulation between
CD40 and CD40L with a monoclonal antibody that is speci¢c
for CD40L and assessed the presence of an immune response by
measuring the presence of anti-Dsg3 antibodies with ELISA
assays. They found that when skin expressing normal Dsg3 was
grafted onto the Dsg3 negative (^/^) background, antibodies
against Dsg3 were generated and were associated with eventual
rejection of the Dsg3 (þ /þ ) skin grafts. However, the titers of
the anti-Dsg3 antibody immune response could be blocked or
signi¢cantly reduced by costimulation blockade in animals trea-
ted with antibodies that bound CD40L.
These experiments represent a positive ¢rst step. In future
studies, it will be important to assess, both quantitatively and
qualitatively, the e¡ects of costimulation blockade on the T-cell
cellular immunity against the Dsg3 (þ /þ ) expressing skin
grafts since graft rejection is likely due to cell-mediated immu-
nity. Another question to answer is how long the Dsg3 (þ /þ )
expressing grafts persisted in the animals that received costimula-
tion blockade. In other words, is it possible that long-term toler-
ance can result when peripheral tolerance is induced by
costimulation blockade immediately after grafting the Dsg3
expressing skin onto Dsg3 (^/^) mice? The authors could also
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determine if the anti-Dsg3 titers, as measured in this study, corre-
late with rejection or maintenance of the Dsg3-expressing skin
grafts. and correspondingly, how well does B-cell tolerance cor-
relate with T-cell tolerance?
Although not speci¢cally stated in this study, the assumption is
that normal Dsg3 was completely lacking in the Dsg3 knock-out
mice. To better understand immune responses and tolerance in-
duction when normal Dsg3 protein is introduced into mice ex-
pressing functionally defective, but full length, Dsg3 protein that
contains a point mutation, one could use an experimental model
in which skin expressing normal Dsg3 is grafted onto knock-in
transgenic mice that express a defective full length Dsg3 protein.
Such studies would help address the issue of whether patients that
express full-length, but defective Dsg3 protein due to a point
mutation would have a lower risk of generating an unwanted im-
mune response, or have immune responses that are easier to sup-
press when they are treated with normal Dsg3 gene replacement.
The current studies represent a good ¢rst step in what will likely
prove to be a long journey aimed at coupling our increasing skill
of gene delivery to improving knowledge about how to induce
and maintain tolerance to normal therapeutic proteins. Future
studies that analyze the blockade of alternative costimulatory
pathways, either alone or in combination could increase our un-
derstanding of how to induce tolerance.
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